Authors

Latest:

Dr. Davis on Comparisons Between Robotic Surgery and Open Surgery in Lung Cancer

J. Russell Davis, MD, clinical professor, University of Missouri–Kansas City School of Medicine, thoracic surgeon, Saint Luke's Hospital, compares the use of robotic surgery with open surgery in patients with lung cancer.

J. Russell Hoverman, MD, PhD

Latest:

Ranking Value in Cancer Care: Analysis of a "Pathways" Approach

Amid a continuing debate over healthcare spending in the United States, the oncology community is growing more introspective about the costs associated with increasingly sophisticated cancer therapeutics.

Jack A. Roth, MD

Latest:

Dr. Roth Compares Surgery With SBRT in Lung Cancer

Jack A. Roth, MD, professor, Department of Thoracic and Cardiovascular Surgery, chief, Section of Thoracic Molecular Oncology, Division of Surgery, University of Texas MD Anderson Cancer Center, compares surgery with stereotactic body radiation therapy (SBRT) in patients with early-stage lung cancer.

Jack Cuzick

Latest:

Dr. Cuzick on Decreasing Breast Cancer Risk With Tamoxifen

Jack Di Palma, MD

Latest:

Effective Management and Prevention of Neratinib-Induced Diarrhea

Safety data from clinical trials suggest that a prophylactic regimen reduces both the severity and duration of neratinib-associated diarrhea.

Jack West, MD, Swedish Cancer Institute

Jackie Rogers

Latest:

Plan Now for MIPS Reporting in 2018

The end of the year is always hectic for oncology practices, but 2017 is proving exceptionally busy as CMS' Quality Payment Program transitional year comes to a close.

Jacob Gersh, PhD

Latest:

Jacob Gersh Discusses the CyberKnife

Jacob Gersh, PhD, lead physicist at the Gibbs Cancer Center & Research Institute, discusses the CyberKnife.

Jacob Laubach, MD, MPP

Latest:

Dr. Laubach on the Efficacy of Daratumumab in Myeloma

Jacob Laubach, MD, MPP, from Dana-Farber Cancer Institute, discusses responses observed following the administration of daratumumab for patients with multiple myeloma.

Jacob Sands, MD

Latest:

Monitoring Patients With RET-Positive NSCLC

Panelists discuss how to monitor patients for response to treatment and early signs of resistance in RET fusion–positive non–small cell lung cancer (NSCLC), including the approach to follow-up molecular testing, and describe strategies for treatment sequencing after disease progression on RET inhibitors.

Jacob Sands, MD, Dana-Farber Cancer Institute

Latest:

Novel Treatment Approaches for SCLC and Future Perspectives

A panel of expert oncologists offer closing thoughts on the future treatment landscape and unmet needs in small-cell lung cancer.

Jacqueline Barrientos, MD, Zucker School of Medicine at Hofstra/Northwell

Jacqueline C. Barrientos, MD

Latest:

Noncovalent BTK Inhibitors in CLL

Recommendations for applying information from clinical trials presented at oncology and hematology conferences in 2021 into routine clinical practice when managing patients with chronic lymphocytic leukemia.

Jacqueline C. Barrientos, MD, MS

Latest:

CAR T-Cell Therapies in CLL

Take-home messages from ASH 2021 regarding the role of CAR T-cell therapies in chronic lymphocytic leukemia.

Jacqueline Claudia Barrientos, MD

Latest:

Dr. Barrientos on Treatment Options for Patients With TP53 Mutations or 17p Deletions in CLL

Jacqueline Claudia Barrientos, MD, MS, discusses treatment options for patients with chronic lymphocytic leukemia who harbor TP53 mutations or 17p deletions.

Jacqueline D. Barrientos, MD, MS

Latest:

Dr. Barrientos on the Challenges in CLL

Jacqueline D. Barrientos, MD, MS, CLL Research and Treatment Program, Northwell Health Systems, discusses the current challenges oncologists are faced with in the field of chronic lymphocytic leukemia.

Jacqueline S. Garcia, MD

Latest:

Dr. Garcia on Future Expectations of Trials and Therapies in Myelofibrosis

Jacqueline S. Garcia, MD, discusses the future expectations of trials and therapies to improve outcomes in myelofibrosis.

Jad Hayes, MS

Latest:

Can New Oncology Payment Programs Help Stabilize Medicare?

Studies have raised doubts about the value Medicare and other payers are getting for the care they pay for, including in oncology. This has intensified the demand for new value-based care models such as the Merit-based Incentive Payment System and the Oncology Care Model.

Jae H. Park, MD

Latest:

Dr Park on the FDA Approval of Obe-Cel in Adult R/R ALL

Jae Park, MD, discusses the FDA approval of obe-cel for adult patients with relapsed or refractory acute lymphoblastic leukemia.

Jae Kim, MD

Latest:

Minimally Invasive Esophagectomy Improves Outcomes, But Remains Underutilized

Surgery remains the most effective curative treatment for esophageal cancer. Yet, many eligible patients do not undergo esophagectomy.